Xlumena, a Mountain View, CA-based developer of advanced endoscopic devices, closed $25m in Series C financing.
The round was led by Third Point, with participation from existing investors Prism VentureWorks, Charter Life Sciences, Ascent Biomedical Ventures and Aperture Venture Partners. In conjunction with the funding, Jason Hong Ph.D. of Third Point LLC, will join Xlumena’s Board of Directors.
The company intends to use the funds to expand global commercialization efforts for its AXIOS family of devices and continue to bring its platform to the US interventional endoscopy community.
Led by Greg Patterson, President and CEO, Xlumena provides the AXIOS Stent and Delivery System, which obtained a CE mark designation in Europe in 2012 and is available in a select number of centers.
The AXIOS Stent, a fully-covered, dual-flanged stent, is delivered under endoscopic ultrasound guidance and designed to create a secure drainage pathway between the gastrointestinal tract and the common bile duct, gallbladder or pseudocyst.
The HOT AXIOS, also available in Europe, incorporates cautery into the delivery system, enabling access and stent delivery in a single device. The AXIOS devices have been used in the treatment of acute cholecystitis, biliary inflammation associated with strictures or stones in the bile duct, and pancreatic pseudocysts.
29/04/2011: Xlumena Closes $7M Series B Financing